This post was originally published on this site
A first-in-human multicenter trial involving Mayo Clinic used a new ablation technique for patients with ventricular tachycardia, an abnormally rapid heart rhythm that is a leading cause of sudden cardiac death worldwide.
The trial tested needle ablation using in-catheter, heated, saline-enhanced, radio frequency energy, also known as SERF, to substantially increase heat transfer, compared to conventional ablation methods. The new process produces deeper, controllable lesion scars at sites inside the heart muscle. The catheter can accurately control the ablation size and treat tissue that is deeper in the heart wall, which is where life-threatening arrhythmias that cause ventricular tachycardia are often found.
Therapies of medication and traditional ablation, which uses heat or cold to scar small areas of heart tissue, may not be enough to prevent ventricular tachycardia. Therefore, many patients also have an implantable cardioverter-defibrillator (ICD) to address dangerous arrhythmias. While an ICD shock corrects the heart’s rhythm, it does not prevent arrhythmia. In the trial, researchers used several methods to directly eliminate abnormal heart tissue that causes life-threatening rhythm.
“This preliminary trial is important because it suggests that there is a new way to treat problematic ventricular tachycardia by reducing or eliminating the shocks that ICDs deliver. It appears to be effective in achieving this goal,” says Douglas Packer, M.D., a cardiac electrophysiologist at Mayo Clinic, first author and principal investigator of the study. “For clinicians, it provides hope that treatment in the electrophysiology lab may be effective, even if other treatments failed. For patients, it provides hope that their quality of life can be improved.”
The innovative catheter was developed by Michael Curley, Ph.D., of Boston-based Thermedical Inc., with funding from the National Institutes of Health (NIH). Dr. Curley is senior author of the research findings that are published in Circulation: Arrhythmia and Electrophysiology.
In the trial, 32 participants from six centers underwent needle electrode ablation. Each had experienced multiple episodes of ventricular tachycardia that did not respond to drug therapy after an ICD was implanted and standard ablation was done. These patients had about 45 shocks from their defibrillator in the six months before their procedure.
For 31 of these 32 patients, their clinical ventricular tachycardia was eliminated immediately at the end of the procedure. Device therapies, such as shock or pace regulation, were reduced by 89% during the five-month follow-up period. Five patients in this high-risk group had complications, primarily in the earlier procedures.
People with ventricular tachycardia live with the potential of sudden cardiac death from irregular electrical signals in the heart. Shocks from an ICD are used to stop arrhythmia, but they do not eliminate the cause of arrhythmia. Corrective shocks are stressful for patients and can reduce quality of life, especially if needed frequently.
“Patients need better treatments for ventricular tachycardia,” says Emily Tinsley, Ph.D., a program officer in the Heart Failure and Arrhythmias Branch of the Division of Cardiovascular Sciences in the National Heart, Lung, and Blood Institute, part of the NIH. Dr. Tinsley was not a member of the study team. “While more research is needed to confirm the findings, this trial gives us preliminary information about a promising new technology for treating this condition.”
Dr. Packer says the next step in this research is a larger clinical trial with approximately 150 patients to prove the findings and demonstrate the safety of the new SERF technology.
Research reported in this release was supported in part by the National Heart, Lung, and Blood Institute (NHLBI), part the National Institutes of Health, under the following grant number: R44HL132746. Funding for this research was also provided by NHLBI’s Small Business Innovation Research (SBIR) Program under the following grants: R43HL63535, R44HL63535, and R44HL132746.
Co-authors of the research paper are David Wilber, M.D., Loyola University Medical Center; Suraj Kapa, M.D., Mayo Clinic; Ammar Killu, M.B.B.S., Mayo Clinic; Katie Dyrda, M.D., Montreal Heart Institute; Isabelle Nault, M.D., Canada Quebec Heart and Lung Institute; Arvindh Kanagasundram, M.D., Vanderbilt University Medical Center; Travis Richardson, M.D., Vanderbilt University Medical Center; and William Stevenson, M.D., Vanderbilt University Medical Center.
Dr. Packer reports that he is an unpaid consultant to Thermedical and has received research funding from NIH/NHLBI and Thermedical. Michael Curley reports grants from the NIH/NHLBI and he currently holds shares in and is the founder of Thermedical Inc.
Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.